USD 22.19 billion
Bronchodilators Market Size, Share, Growth Analysis, By Drug Type(Beta2-Adrenergic Agonists, Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor), By Route of Administration(Oral, Injection, and Inhaler.), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2257 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
65
|Figures:
70
Bronchodilators Market Insights
Bronchodilators Market size was valued at USD 23.48 Billion in 2023 and is poised to grow from USD 24.84 Billion in 2024 to USD 39 Billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).
The bronchodilators market is witnessing significant growth due to the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. Bronchodilators are medications that relax and widen the airways in the lungs, facilitating improved breathing. The increasing global burden of these respiratory ailments, coupled with changing lifestyles and environmental factors, is driving the demand for bronchodilator medications.
The market is categorized into short-acting and long-acting bronchodilators, each catering to specific patient needs. Short-acting bronchodilators provide quick relief during acute breathing difficulties, while long-acting bronchodilators offer extended benefits for chronic management.
North America and Europe hold substantial market shares, driven by a high prevalence of respiratory disorders, well-established healthcare infrastructure, and increased awareness. Asia-Pacific is emerging as a lucrative market due to growing pollution levels and lifestyle changes in densely populated regions.
Moreover, advancements in inhalation devices, such as metered-dose inhalers and dry powder inhalers, are enhancing drug delivery efficiency and patient compliance. As the burden of respiratory disorders continues to rise, the bronchodilators market is poised for further expansion, driven by continuous research, innovative drug formulations, and strategic collaborations within the pharmaceutical industry.
US Bronchodilators Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Beta-adrenergic Bronchodilators
Fastest Growth
Anticholinergics
Growth Rate
5.8% CAGR
Global Bronchodilators Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Bronchodilators Market Segmental Analysis
The global bronchodilators market is segmented on the basis of Indication, Drug Type, Route of Administration, and Region. Based on Indication the market is segmented as, Asthma, Chronic obstructive pulmonary disease (COPD), others. Based on Drug Type, the market is segmented as, Beta2-Adrenergic Agonists, Anticholinergic Agents, Methylxanthines, Combination Bronchodilators. Based on Route of Administration, the market is segmented as, Oral, Injection, Inhaler. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Bronchodilators Market Analysis By Drug Type
In 2022, the beta-adrenergic bronchodilators segment held a dominant market position, accounting for over 40.0% of the total revenue. This category is projected to exhibit the highest compound annual growth rate (CAGR) of 3.33% during the forecast period. Beta-adrenergic bronchodilators function by relaxing the muscles surrounding the airways, leading to the dilation of bronchial airways. These medications, classified as beta-2 agonists, target receptors on smooth muscle cells to achieve airway dilation. Notable products within the short-acting segment include albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin HFA), levalbuterol (Xopenex HFA), and epinephrine injection. Albuterol, a prominent molecule within this category, is witnessing a surge in generic approvals and new launches by the FDA to meet growing demand. For instance, Teva Pharmaceutical Industries Ltd. introduced ProAir Digihaler (albuterol sulfate) inhalation powder in May 2022 for asthma treatment.
The anticholinergic bronchodilators segment is poised for lucrative growth over the forecast period. This growth is underpinned by the availability of both long and short-acting anticholinergic formulations. These bronchodilators work by inhibiting parasympathetic nerve reflexes, preventing airway constriction and maintaining airway openness. Anticholinergic bronchodilators are commonly employed as a primary treatment for chronic obstructive pulmonary disease (COPD). However, it's important to note that the segment's growth is restrained by potential health consequences, particularly among the elderly population. Studies have linked anticholinergics to increased fall-related hospitalizations, a higher risk of dementia, and elevated mortality rates in this demographic.
Bronchodilators Market Analysis By Route of Administration
In 2022, the nasal (inhalable) segment held the largest market share, accounting for 51.8% of the total. This segment is projected to achieve the highest compound annual growth rate (CAGR) of 3.28% during the forecast period. The nasal or inhalable route stands as the most prevalent method of administering bronchodilators. This route encompasses various administration forms, including metered-dose inhalers (MDIs), nebulizers, dry powder inhalers, and soft mist inhalers. Research highlighted by the International Journal of Chronic Obstructive Pulmonary Disease indicates that soft mist inhaler aerosols deliver doses that last longer and move at a slower pace compared to MDIs. The introduction of generic versions of nasal formulations further fuels market expansion. For instance, Mylan's FDA-approved generic version of Symbicort, an inhalation aerosol, was launched in March 2022 for treating asthma and COPD.
The oral segment is poised for substantial growth over the forecast period. This projection is grounded in the segment's status as the second most preferred administration route among clinicians and patients, owing to its ability to avoid the adverse effects associated with injectable administration. Additionally, oral medications are often more cost-effective, with a plethora of generic alternatives available. Their popularity is driven by their relatively lower expenses and the avoidance of injection-related complications. As the bronchodilators market evolves, these segments are expected to play pivotal roles in shaping its growth trajectory.
Global Bronchodilators market By Drug Type
To get detailed analysis on other segments, Request For Free Sample Report
Bronchodilators Market Regional Insights
In 2022, North America emerged as the dominant force in the bronchodilators market. This supremacy is attributed to several factors, including the increasing prevalence of conditions like COPD and asthma, a growing elderly population, and a surging demand for high-efficiency and rapid-action drugs. The rising COPD cases in the region can be linked to various environmental factors such as air pollution, exposure to chemicals, dust, fumes, secondhand smoke, and a history of childhood lung infections. Notably, cigarette smoking has been identified as the primary cause of 85 to 90% of all COPD cases, with a substantial number of smokers in North America, estimated to be around 30.8 million adults in the U.S. Furthermore, over 16 million individuals in the region suffer from smoking-related diseases.
Asia Pacific is poised to witness the most rapid growth during the forecast period. This projection stems from the region's high prevalence of asthma, where the condition stands as a leading cause of mortality and a significant non-communicable disease. The presence of key players like Glenmark Pharmaceuticals Limited and Cipla Inc. within the region provides a competitive edge, as these companies specialize in offering low-cost generic bronchodilators. The introduction of advanced inhaler bronchodilators further propels market growth. For example, in October 2020, Zydus Cadila launched Forglyn pMDI, a pressurized metered-dose inhaler, priced at Rs 495 per pack, aimed at addressing COPD patients in India. These developments position Asia Pacific as a key growth driver in the bronchodilators market landscape.
Global Bronchodilators market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Bronchodilators Market Dynamics
Bronchodilators Market Drivers
Rising Prevalence of Respiratory Disorders:
- The increasing incidence of respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis is a major driver for the bronchodilators market. The growing global burden of these conditions necessitates effective bronchodilator medications for symptom relief and disease management.
Aging Population:
- The world's aging population contributes to the rise in respiratory disorders, as the elderly are more susceptible to these conditions. The growing elderly demographic fuels the demand for bronchodilators that offer relief and improved quality of life.
Bronchodilators Market Restraints
Side Effects and Safety Concerns:
- Some bronchodilators, particularly those inhaled, can lead to adverse effects such as tremors, increased heart rate, and headaches. These side effects can deter patients from consistent usage or lead to non-compliance with treatment regimens.
Limited Efficacy for All Patients:
- Bronchodilators may not be equally effective for all patients, especially in severe cases of respiratory disorders. Some patients might require multiple medications or alternative treatment approaches, leading to challenges in finding the most suitable bronchodilator regimen.
Request Free Customization of this report to help us to meet your business objectives.
Bronchodilators Market Competitive Landscape
The competitive landscape of the bronchodilators market is characterized by the presence of numerous pharmaceutical companies striving to develop and market effective medications for respiratory disorders. Key players in the market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, and Teva Pharmaceutical Industries Ltd., among others. These companies engage in strategic initiatives such as mergers, acquisitions, collaborations, and product launches to strengthen their market position and expand their product portfolios. They focus on developing innovative inhalation devices, generic versions of popular bronchodilators, and combination therapies to cater to the diverse needs of patients with respiratory conditions. Additionally, partnerships with healthcare professionals and patient advocacy groups help these companies enhance disease awareness and promote appropriate usage of bronchodilators. The evolving landscape of respiratory care and increasing competition drive companies to invest in research and development, striving to introduce novel formulations, delivery mechanisms, and personalized treatment options that offer patients better symptom relief and improved quality of life.
Bronchodilators Market Top Player’s Company Profile
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Novartis
- Merck & Co.
- Mylan N.V.
- Sunovion Pharmaceuticals
- Cipla
- Vectura Group
- Chiesi Farmaceutici
- Mundipharma
- Perrigo
- Orion Corporation
- Almirall
Bronchodilators Market Recent Developments
- In January 2023, AstraZeneca announced the launch of a new long-acting beta2-agonist (LABA) bronchodilator called tezepelumab. Tezepelumab is the first LABA that is specifically designed to target a protein called thymic stromal lymphopoietin (TSLP). TSLP is thought to play a role in the development of asthma and chronic obstructive pulmonary disease (COPD).
- In February 2023, Boehringer Ingelheim announced the launch of a new combination inhaler called glycopyrronium/formoterol fumarate (G/F). G/F is a combination of a long-acting muscarinic antagonist (LAMA) and a LABA. It is the first combination inhaler to be approved for the treatment of asthma in children aged 6 years and older.
- In March 2023, Novartis announced the launch of a new dry powder inhaler called tiotropium bromide. Tiotropium bromide is a long-acting anticholinergic (LAMA) that is used to treat asthma and COPD. It is the first LAMA to be approved for the treatment of asthma in children aged 6 years and older.
Bronchodilators Key Market Trends
- Advancements in Inhaler Technology: Inhalation devices are a pivotal component of bronchodilator administration. The market is witnessing a trend towards advanced inhaler technologies, such as smart inhalers and digital monitoring systems. These innovations offer real-time monitoring of medication usage and provide feedback to both patients and healthcare professionals, enhancing treatment adherence and disease management.
Bronchodilators Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global bronchodilators market analysis, North America and Asia Pacific are prominent players due to the high prevalence of respiratory disorders like asthma and COPD, along with advanced healthcare infrastructure. The market is segmented based on product type, including beta-adrenergic bronchodilators, anticholinergic bronchodilators, and others. Among these, beta-adrenergic bronchodilators hold the largest share due to their widespread use in dilating bronchial airways.
Key drivers of the bronchodilators market include the increasing incidence of respiratory disorders, rising pollution levels, smoking-related health issues, and the growing geriatric population. Moreover, technological advancements in inhalation devices, personalized treatment approaches, and the development of combination therapies are propelling market growth. The trend toward telehealth and digital health solutions is also contributing to enhanced disease management and treatment adherence.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 22.19 billion |
| Market size value in 2031 | USD 36.86 billion |
| Growth Rate | 5.8% |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Bronchodilators Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Bronchodilators Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Bronchodilators Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bronchodilators Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bronchodilators Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Bronchodilators Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
